Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 10/20 | 0.50 |
| ▸ | SELE | P16581 | 6/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962136 | 0.93 | MAG (0.54) | MAGSELESELLSELP | |
| SCHEMBL12257341 | 0.90 | SELE (0.48) | MAGSELESELLSELP | |
| SCHEMBL12257326 | 0.87 | SELE (0.46) | MAGSELESELLSELP | |
| SCHEMBL11962144 | 0.83 | MAG (0.53) | MAGSELESELLSELP | |
| SCHEMBL11962138 | 0.80 | MAG (0.50) | MAGSELESELLSELP | |
| SCHEMBL12257344 | 0.79 | SELL (0.52) | MAGSELESELLSELP | |
| SCHEMBL13950212 | 0.77 | SELP (0.51) | MAGSELESELLSELP | |
| SCHEMBL12257323 | 0.76 | SELP (0.49) | MAGSELESELLSELP | |
| SCHEMBL9613545 | 0.75 | SELE (0.57) | SELESELP | |
| SCHEMBL12902993 | 0.75 | SELE (0.55) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7964569-B2 | Oligosaccharide mimetics such as {(1R,2R,3S)-2-[(6-Deoxy- alpha -L-Galactopyranosyl)Oxy]-3-Ethyl-Cyclohex-1-yl}2-O-Benzoyl-3-O-[(1S)-1-Carboxy-2-Cyclohexyl-Ethyl]- beta -D-Galactopyranoside | GLYCOMIMETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | FUT6, B3GNT2, FUT5 | MAG 163/4885SELE 622/4885SELL 1056/4885 |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | FUT6, ENGASE, FUT5 | MAG 173/4885SELE 158/4885SELL 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.